Home Tags Pfizer
Dispensed: Hospital CIOs dish on the cloud, digital chiefs talk tech in healthcare, and how our editor picked his health plan
Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
The new company will sell popular drugs such as Viagra, Lipitor, and Mylan's EpiPen, and is expected to generate around $20 billion in total sales.
The companies set to report earnings include big names like Apple, ExxonMobil, Berkshire Hathaway, and Verizon.
Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here’s how the Botox-ma...
Here's how Allergan went from its start as a sleepy but beloved company out of Southern California in the 1950s to an acquisition target for AbbVie.
Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer
Pfizer's blockbuster deal for Array BioPharma is the latest in a growing list of M&A deals to take place in the cancer-treatment space this year.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
Drug giant Pfizer isn’t ready to abandon neuroscience — here’s its $150-million ‘star cluster’ strategy for betting on p...
Execs from pharma giant Pfizer shared their strategy for keeping an eye on neuroscience — if not from the front row, then at least from the sidelines.
Trump may have shamed Pfizer for increasing drug prices, but that isn’t stopping drugmakers from doing more of the same
Pharmaceutical companies are increasing drug price again this month, and they could be even larger than usual.
Two huge drugmakers are spinning off iconic brands like Advil, ChapStick and Emergen-C with nearly $13 billion in sales — and it’s part of...
The products involved in the deal are familiar pharmacy names, but they also have lower margins than other medicines.
GlaxoSmithKline will be broken up in a megadeal with Pfizer that could change the face of global healthcare
The joint venture could have combined sales of nearly $10 billion.